Abstract: The present invention relates to the use of a combination of two or more of a D2 agonist, an adenosine A2A receptor antagonist, a histamine H3 antagonist or inverse agonist, a mGluR5 receptor antagonist, or a nicotinic ?4-?2 and/or ?7 receptor agonist to increase D2 dopaminergic molecular signaling in the striatum for the treatment of psychiatric or neurological disorders in which anhedonia or motivation-related dysfunction exists (such as major depressive disorder, bipolar I or II disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative symptoms) and Parkinson's disease (e.g. non-motor features such as depression and apathy)).

Abstract: A system for inline measurement of gap width and flush depth of adjacent surfaces of a vehicle continuously moving longitudinally relative to the system comprises at least one laser source, at least one image sensor, and a processor configured to perform measurements within a predetermined cycle time. The processor controls the laser profiler to project laser beams onto vehicle surfaces, acquires optical images of reflected beams from the image sensor, and matches gap profiles from stored one-dimensional profiles to identify gaps. The system performs gap width and flush depth measurements and outputs anomaly detection signals when measurements deviate from predetermined target values. The system includes bias correction capabilities using empirically determined values and CAD-based target values for specific vehicle models. Dynamic adjustments are made based on vehicle color, with laser brightness optimized for surface reflectivity.

Abstract: A method and system for estimating dimensions of vehicle exterior defects using multiple cameras arranged in a predefined configuration. The method comprises receiving images from multiple strategically positioned image sensors including side cameras parallel to a vehicle height axis, diagonal cameras at an inclined angle, and roof top cameras perpendicular to the height axis. An angle to detected defects is computed based on image sensor parameters. Different distance calculations are applied based on vehicle section location, with specialized formulas for windshield, back window, and roof components. Defect sizes are computed by determining multiple defect dimensions, with at least one dimension being adjusted by an angular correction factor derived from the relationship between camera angle and vehicle surface orientation.

Abstract: Disclosed are system and method for metrology of 3D structural elements of a wafer by projecting, on a subset of the 3D structural elements, a focused ion beam (FIB) at a predefined diagonal angle, thereby generating a diagonal cut in each of the subset of sites, scanning each of the diagonal cuts using a scanning electron microscope (SEM), generating a reconstruction of the one or more 3D structural elements or a component thereof based on the SEM image and performing metrology measurements on the reconstruction.

Abstract: A method and system for estimating dimensions of vehicle exterior defects using multiple cameras arranged in a predefined configuration. The method comprises receiving images from multiple strategically positioned image sensors including side cameras parallel to a vehicle height axis, diagonal cameras at an inclined angle, and roof top cameras perpendicular to the height axis. An angle to detected defects is computed based on image sensor parameters. Different distance calculations are applied based on vehicle section location, with specialized formulas for windshield, back window, and roof components. Defect sizes are computed by determining multiple defect dimensions, with at least one dimension being adjusted by an angular correction factor derived from the relationship between camera angle and vehicle surface orientation.

Abstract: A method of estimating dimensions of vehicle's exterior defects based on reference dimensions comprising analyzing one or more images captured by one or more image sensors deployed to depict a vehicle to identify one or more reference feature relating to the vehicle, obtaining real-world size of the reference feature(s), computing a pixel to real-world size ratio for the image sensor(s) based on the real-world size of the reference feature(s) and a size in pixels of the reference feature(s) in the image(s), analyzing one or more images captured by the image sensor(s) to identify one or more defects in an exterior of the vehicle, computing a size in pixels of one or more dimensions of each defect; and computing a real-world size of the dimension(s) based on the size in pixels of the respective dimension and the pixel to real-world size ratio.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

Abstract: A method of estimating dimensions of vehicle's exterior defects based on reference dimensions comprising analyzing one or more images captured by one or more image sensors deployed to depict a vehicle to identify one or more reference feature relating to the vehicle, obtaining real-world size of the reference feature(s), computing a pixel to real-world size ratio for the image sensor(s) based on the real-world size of the reference feature(s) and a size in pixels of the reference feature(s) in the image(s), analyzing one or more images captured by the image sensor(s) to identify one or more defects in an exterior of the vehicle, computing a size in pixels of one or more dimensions of each defect; and computing a real-world size of the dimension(s) based on the size in pixels of the respective dimension and the pixel to real-world size ratio.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino) pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

Abstract: The present invention relates to the use of a combination of a phosphodiesterase 4 (PDE4) inhibitor and one or more of 5-HT4 agonist, an H3 antagonist or inverse agonist, a nicotinic ?7 receptor agonist, a ?3 adrenergic agonist or a TAAR1 agonist for the treatment of psychiatric or neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists (such as major depressive disorder, bipolar I disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative and cognitive symptoms), as well as Parkinson's disease (e.g. non-motor features such as depression, apathy and cognitive impairment)).

Abstract: This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder, bipolar disorder, posttraumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms), in a patient who is cognitively impaired or has poor or slow cognition or difficulty making decisions or exhibits certain EEG properties. The present invention also relates to the selection of patients with a biomarker (e.g., EEG) and/or clinical symptoms who would most benefit from such compounds.

Abstract: The present invention relates to the use of a combination of two or more of a D2 agonist, an adenosine A2A receptor antagonist, a histamine H3 antagonist or inverse agonist, a mGluR5 receptor antagonist, or a nicotinic ?4-?2 and/or ?7 receptor agonist to increase D2 dopaminergic molecular signaling in the striatum for the treatment of psychiatric or neurological disorders in which anhedonia or motivation-related dysfunction exists (such as major depressive disorder, bipolar I or II disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative symptoms) and Parkinson's disease (e.g. non-motor features such as depression and apathy)).

Abstract: The present invention relates to the use of a combination of a phosphodiesterase 4 (PDE4) inhibitor and one or more of 5-HT4 agonist, an H3 antagonist or inverse agonist, a nicotinic ?7 receptor agonist, a ?3 adrenergic agonist or a TAAR1 agonist for the treatment of psychiatric or neurological disorders in which depressive, anhedonia, motivation-related or cognition-related dysfunction exists (such as major depressive disorder, bipolar I disorder, post-traumatic stress disorder, addiction, anhedonia or motivation-related aspects of schizophrenia (e.g. negative and cognitive symptoms), as well as Parkinson's disease (e.g. non-motor features such as depression, apathy and cognitive impairment)).

Abstract: A method, a non-transitory computer readable medium and a detection system for determining locations of suspected defects of a substrate.

Abstract: A method, a non-transitory computer readable medium and a detection system for determining locations of suspected defects of a substrate.

Abstract: A real-time wireless positioning system, comprising: a plurality of portable tag devices; a plurality of autonomous reference transmitters installed in a defined area housing said plurality of tag devices; a plurality of anchors installed in a defined area housing said plurality of tag devices and said a plurality of autonomous reference transmitters; and at least one location engine unit in an area housing said plurality of tag devices, said a plurality of autonomous reference transmitters and said plurality of anchors.